Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

AIDS

Volumn 15, Issue 11, 2001, Pages 1389-1398

  Lichtenstein, Kenneth A ^a   Ward, Douglas J ^b   Moorman, Anne C ^c   Delaney, Kathleen M ^c   Young, Benjamin ^a   Palella Jr, Frank J ^d   Rhodes, Philip H ^c   Wood, Kathleen C ^e   Holmberg, Scott D ^f  

^a ROSE MEDICAL CENTER   (United States)

^b Dupont Circle Physicians Group   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e APACHE Medical Systems   (United States)

^f Rose Medical Center ^*

Author keywords

Antiretroviral drugs; Complications; Fat accumulation; HIV infection; Lipoatrophy; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTI-HIV AGENTS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LIPODYSTROPHY; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STAVUDINE; VIRAL LOAD;

EID: 0035958793     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107270-00008     Document Type: Article

References (17)

1. Protease inhibitors may increase blood glucose in HIV patients
2. Associated lipodystrophy metabolic disorders due to protease inhibitor containing regimens
3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
4. Protease inhibitor-associated hyperglycaemia
5. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors
6. 'Buffalo hump' in men with HIV-1 infection
7. Pseudo-Cushing's Syndrome in human immunodeficiency virus-infected patients
8. 'Buffalo humps' associated with protease inhibitors
9. High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy
10. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside-analogue therapy
11. A syndrome of lipodystrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
12. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
13. Changing conditions and therapies of ambulatory HIV-infected patients: The HIV Outpatient Study (HOPS)
14. Declining mortality and morbidity in HIV-infected ambulatory patients
15. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
16. Alteration of tumor necrosis factor alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome